CLC and mesothelioma: Based on experimental evidence in cell culture and mice, we demonstrate that eosinophil-derived CLC-P/Gal10 promotes resistance to the standard chemotherapy of mesothelioma (i.e., the C + P regimen) and, more importantly, that an anti-eosinophilic treatment allows to improve the therapeutic response in a preclinical mouse model.